NASDAQ: LXRX. Lexicon's Common Stock. Last price ... Investor Relations lexinvest@lexpharma.com. Media ... Report a ConcernAdverse Event ReportingPricing ...
People also ask
Is LXRX a good buy?
Why is LXRX stock dropping?
What are the predictions for LXRX?
When did the FDA approve LXRX?
NASDAQ: LXRX. Lexicon's Common Stock. Last price. $1.65. Change today. 1.23%. Investor Relations ... Report a ConcernAdverse Event ReportingPricing Disclosures.
Lexicon Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 05/07/2024. The upcoming earnings date is derived from an algorithm based on a ...
LXRX on Nasdaq. This company's Exchange Act ... [+] 10-K (annual reports) and 10-Q (quarterly reports) ... Before you Invest, Investor.gov. Get answers to your ...
Apr 11, 2018 · Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects.
Missing: relations | Show results with:relations
Get the latest insights on Lexicon Pharmaceuticals, Inc. Common Stock (LXRX) with press releases and corporate news to help you in your trading and ...
... Investor Relations and Corporate Strategy THE WOODLANDS, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today ...
Investor Relations URL, N/A. HQ State/Province, Texas. Sector, Health Care. Industry, Biotechnology. Equity Style, Small Cap/Growth. Next Earnings Release, May.
Lexicon Pharmaceuticals, Inc. (US:LXRX) has 221 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission ...
For Investor Inquiries: Kimberly Lee, D.O.. Head of Investor Relations and Corporate Strategy. Lexicon Pharmaceuticals. (281) 863-3383. klee@lexpharma.com. For ...